Pharmacoeconomic considerations of multiple sclerosis therapy with the new disease-modifying agents

By Amato Maria Pia  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2115-2126

Informa Healthcare

Access to resources Recommend Favorite

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

By Phillips C.J.  

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 561-574

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents in the Treatment of Multiple Sclerosis: A Review of Long-Term Outcomes

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 8, Iss. 6, 2009-12 ,pp. : 512-519

Bentham Science Publishers

Access to resources Recommend Favorite

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

By Russo P.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance

By Lu Ellen   Wang Bing Wei   Guimond Colleen   Synnes Anne   Sadovnick A Dessa   Dahlgren Leanne   Traboulsee Anthony   Tremlett Helen  

Expert Review of Neurotherapeutics, Vol. 13, Iss. 3, 2013-03 ,pp. : 251-261

Informa Healthcare

Access to resources Recommend Favorite